CHAMPIONS ONCOLOGY, INC.

Champions Oncology, Inc.

What the company does

• Technology-enabled research organization focused on oncology drug discovery and development.
• Maintains a proprietary bank of Patient Derived Xenograft (PDX) models (TumorBank) used in in vivo and ex vivo pharmacology studies to assess therapeutic efficacy and biomarkers.
• Integrates large-scale multi-omic and clinical data (Datacenter) with analytics to support drug discovery, biomarker development, and patient stratification.
• Revenue streams:
  • Research Services: In vivo, ex vivo, analytical, and computational studies to predict efficacy, identify responsive cancer subtypes, and support target discovery, patient population selection, and biomarker hypotheses.
  • Data Licenses: Licensing access to PDX model data via a comprehensive multi-omic dataset linked to clinical information.
  • Software as a Service (SaaS): Lumin Bioinformatics platform, a subscription-based data and analytics tool powered by the Datacenter for computational cancer research.
• Also conducts Drug Discovery and Development focused on targeted therapies, immuno-oncology, and cell therapy, supported by a dedicated R&D team.

Key platforms and data assets

• TumorBank: About 1,500 PDX models, characterized at phenotypic, molecular, and pharmacologic levels; includes models from patients resistant to certain therapies.
• Datacenter: Combines proprietary TumorBank data with public datasets and includes approximately:
  • 3,500 molecular datasets (genomics, transcriptomics, proteomics, phosphoproteomics)
  • 3,000 clinical drug responses
  • 3,500 in vivo drug responses
  • Rich clinical information on patients (age, gender, ethnicity, tumor specifics, etc.)
  • Approximately 20,000 publicly available datasets (genomics, transcriptomics, proteomics, functional genomics, patient outcomes)
  • Living dataset: models are characterized continuously over time
• Lumin Bioinformatics (SaaS): Analytics and Datacenter-powered software for computational cancer research; supports biomarker hypotheses, insights into resistance mechanisms, and guidance for preclinical evaluations.

Business lines

• Translational Oncology Solutions (TOS)
• Research Services (core revenue driver)
• Data Licenses
• SaaS (Lumin Bioinformatics)
• Drug Discovery and Development (target areas: targeted therapy with drug conjugates, immuno-oncology, cell therapy)

Customers and workforce

• Customers: Performed studies for approximately 500 different pharmaceutical and biotechnology companies over the past ten years.
• Employees: 214 full-time employees as of July 15, 2026
  • 103 with doctoral or other advanced degrees
  • 149 in research and development or laboratory operations
  • 45 in sales and marketing
  • 20 in finance, IT, and administration
• Commercial capacity: Approximately 45 sales professionals engaged in direct outreach to customers.

Financial snapshot (fiscal year ended April 30)

• Revenue: Approximately $59.4 million (FY2026), up about 4% from the prior year.
• Net income: Net loss of approximately $1.2 million (FY2026).
• Accumulated deficit: Approximately $81.1 million.
• Cash and equivalents: Approximately $4.9 million.
• Cash used in operating activities: Approximately $4.5 million for the twelve months ending April 30, 2026.
• Revenue mix: Largely derived from research services; typical study sizes average around $125,000, with many studies in the $250,000 to $500,000 range. Regulatory-environment studies can be larger.

Strategic and operational focus

• Growth priorities:
  • Expand TumorBank breadth (new cancer subtypes, resistant models) and depth of characterization.
  • Add new proprietary pharmacology platforms and analytical capabilities.
  • Enhance computational power and analytics using the Datacenter and Lumin.
• Market positioning: Competes in research services, SaaS data analytics, and drug discovery/development within the global oncology landscape; operates in both non-regulatory and regulatory environments as needed.
• Intellectual property: Proprietary TumorGraft technology is not patented; the company relies on trade secrets and know-how and protects data and analytics through standard confidentiality practices and agreements.

Headquarters and facilities

• Headquarters: One University Plaza, Hackensack, New Jersey.
• Primary laboratory and operations site: 1330 Piccard Drive, Rockville, Maryland.
• International: Milan, Italy (flow cytometry services) with a lease terminated in 2026.

Notes

• The company maintains a living, highly characterized TumorBank linked to a broad Datacenter and a SaaS analytics layer (Lumin) to accelerate oncology drug discovery and development for its customers.